Learn More -

HIV antidiarrheal Mytesi

By: Positively Aware (NOV+DEC 2016)

Previously known as Fulyzaq (generic name crofelemer), the only FDA-approved drug for treating HIV-related diarrhea has been acquired by Napo Pharmaceuticals and is now marketed under the name Mytesi. The company has launched patient co-pay and patient assistance programs to allow for broader access to Mytesi. For details, go to mytesi.com/mytesi-savings.html.

Read More

FDA-Approved Mytesi Relieves Noninfectious Diarrhea in HIV-Positive Patients

By: EDGE Media Network

Yesterday, Napo Pharmaceuticals, Inc., announced the launch and general availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV-positive patients. Previously marketed as Fulyzaq, the product launch under the Mytesi brand importantly includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug.

Read More
Optimization WordPress Plugins & Solutions by W3 EDGE